DOCSLIB.ORG

Federal Register/Vol. 85, No. 111/Tuesday, June 9, 2020/Notices

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 85, No. 111/Tuesday, June 9, 2020/Notices 35332 Federal Register / Vol. 85, No. 111 / Tuesday, June 9, 2020 / Notices notice that the entity identified below Honeoye, New York 14471, applied to DATES: Registered bulk manufacturers of has applied for registration as a bulk be registered as a bulk manufacturer of the affected basic class(es), and manufacturer of schedule I controlled the following basic class(es) of applicants therefore, may file written substances. In response, registered bulk controlled substances: comments on or objections to the manufacturers of the affected basic issuance of the proposed registration on class(es), and applicants therefor, may Drug or before July 9, 2020. Such persons Controlled substance code Schedule file written comments on or objections may also file a written request for a of the requested registration, as Marihuana ........................ 7360 I hearing on the application on or before provided in this notice. This notice does July 9, 2020. not constitute any evaluation or The applicant noticed above applied determination of the merits of the ADDRESSES: Written comments should to become registered with DEA to grow application submitted. be sent to: Drug Enforcement marihuana as a bulk manufacturer The applicant plans to manufacture Administration, Attention: DEA Federal bulk active pharmaceutical ingredients subsequent to a 2020 DEA notice of proposed rulemaking that provided Register Representative/DPW, 8701 (APIs) for product development and Morrissette Drive, Springfield, Virginia distribution to DEA registered information on how DEA intends to expand the number of registrations, and 22152. All requests for a hearing must researchers. If the application for be sent to: Drug Enforcement registration is granted, the registrant described the way it would oversee those additional growers. If finalized, Administration, Attn: Administrator, would not be authorized to conduct 8701 Morrissette Drive, Springfield, other activity under this registration the proposed rule would govern persons Virginia 22152. All requests for a aside from those coincident activities seeking to become registered with DEA hearing should also be sent to: (1) Drug specifically authorized by DEA to grow marihuana as a bulk regulations. DEA will evaluate the manufacturer, consistent with Enforcement Administration, Attn: application for registration as a bulk applicable law. The notice of proposed Hearing Clerk/OALJ, 8701 Morrissette manufacturer for compliance with all rulemaking is available at 85 FR 16292. Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, applicable laws, treaties, and William T. McDermott, Attn: DEA Federal Register regulations and to ensure adequate Assistant Administrator. safeguards against diversion are in Representative/DPW, 8701 Morrissette [FR Doc. 2020–12383 Filed 6–8–20; 8:45 am] place. Drive, Springfield, Virginia 22152. As this applicant has applied to BILLING CODE 4410–09–P SUPPLEMENTARY INFORMATION: In become registered as a bulk accordance with 21 CFR 1301.34(a), this manufacturer of marihuana, the DEPARTMENT OF JUSTICE application will be evaluated under the is notice that on May 15, 2020, Research Triangle Institute, 3040 East Cornwallis criteria of 21 U.S.C. 823(a). DEA Drug Enforcement Administration proposes to conduct this evaluation in Road, Hermann Building, Room 106, the manner described in the rule [Docket No. DEA–661] Research Triangle Park, North Carolina proposed at 85 FR 16292, published on 27709–2194, applied to be registered as Importer of Controlled Substances March 23, 2020, if finalized. an importer of the following basic In accordance with 21 CFR Application: Research Triangle class(es) of controlled substances: 1301.33(a), DEA is providing notice that Institute on May 7, 2020, Honeoye ACTION: Notice of application. Manufacturing, 4825 County Road 36, Controlled substance Drug code Schedule 3-Fluoro-N-methylcathinone (3–FMC) ............................................................................................................................. 1233 I Cathinone ........................................................................................................................................................................ 1235 I Methcathinone ................................................................................................................................................................. 1237 I 4-Fluoro-N-methylcathinone (4–FMC) ............................................................................................................................. 1238 I Pentedrone (a-methylaminovalerophenone) ................................................................................................................... 1246 I Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 1248 I 4-Methyl-N-ethylcathinone (4–MEC) ............................................................................................................................... 1249 I Naphyrone ....................................................................................................................................................................... 1258 I N-Ethylamphetamine ....................................................................................................................................................... 1475 I N,N-Dimethylamphetamine .............................................................................................................................................. 1480 I Fenethylline ..................................................................................................................................................................... 1503 I Aminorex .......................................................................................................................................................................... 1585 I 4-Methylaminorex (cis isomer) ........................................................................................................................................ 1590 I Gamma Hydroxybutyric Acid ........................................................................................................................................... 2010 I Methaqualone .................................................................................................................................................................. 2565 I Mecloqualone .................................................................................................................................................................. 2572 I JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .................................................................................................. 6250 I SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................ 7008 I ADB–FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) .............. 7010 I 5-Fluoro-UR–144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................ 7011 I AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ..................... 7012 I FUB–144 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone) ............................................... 7014 I JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ...................................................................................................................... 7019 I MDMB–FUBINACA (Methyl 2-(1-(4-fluorobenzyl)-1H indazole-3-carboxamido)-3,3-dimethylbutanoate) ...................... 7020 I FUB–AMB, MMB- FUBINACA, AMB–FUBINACA (2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3- 7021 I methylbutanoate). AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole3-carboxamide) .......................................... 7023 I VerDate Sep<11>2014 23:08 Jun 08, 2020 Jkt 250001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\09JNN1.SGM 09JNN1 jbell on DSKJLSW7X2PROD with NOTICES Federal Register / Vol. 85, No. 111 / Tuesday, June 9, 2020 / Notices 35333 Controlled substance Drug code Schedule THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ................................................................... 7024 I 5F–AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2 yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide) ................... 7025 I AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)1H-indazole-3-carboxamide .................. 7031 I MAB–CHMINACA (N-(1-amino-3,3dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide) ........ 7032 I 5F–AMB (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3 carboxamido)-3-methylbutanoate) .............................................. 7033 I 5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5 fluoropentyl)-1H-indazole-3-carboxamido)-3,3dimethylbutanoate) ....... 7034 I ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ................................. 7035 I 5F–EDMB–PINACA (ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) ......................... 7036 I 5F–MDMB–PICA (methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate) .............................. 7041 I MDMB–CHMICA, MMB–CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)- 7042 I 3,3dimethylbutanoate).
Load more

Recommended publications
  • Acquired Synaesthesia Following 2C-B Use
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Greenwich Academic Literature Archive Acquired synaesthesia following 2C-B use • Authors • Authors and affiliations • Steliana Yanakieva (Department of Psychology, Goldsmiths, University of London) • David P. Luke (Department of Psychology, Social Work and Counselling, University of Greenwich) • Ashok Jansari (Department of Psychology, Goldsmiths, University of London) • Devin B. Terhune (Department of Psychology, Goldsmiths, University of London) Letter to Editor This study was previously presented at Bridging senses: New developments in synesthesia (Royal Society, London, UK, 22–23 October 2018). Psychedelic drugs reliably trigger experiences that closely resemble synaesthesia (Luke and Terhune 2013), a condition in which inducer stimuli will reliably and automatically elicit atypical concurrent experiences (Ward 2013). These transient episodes are considered controversial because they do not meet behavioural diagnostic criteria for developmental synaesthesia (Terhune et al. 2016). However, if these behavioural markers are attributable to the consolidation of synaesthetic associations over time (Terhune et al. 2016), they should be observed in cases of acquired synaesthesia. Here we report a case of drug-induced acquired synaesthesia (LW) that meets standard diagnostic criteria for developmental synaesthesia. LW is a 29-year-old male who reports continuously experiencing multiple forms of synaesthesia for over 7 years since ingesting approximately 70–150 mg of 2,5-dimethoxy-4- bromophenethylamine (2C-B) (Papaseit et al. 2018), which greatly exceeds the normal dosage (12–24 mg) (Shulgin and Shulgin 1990) (see Supplementary Materials). LW was contrasted against 10 non-synaesthete healthy controls, all of whom provided informed written consent.
    [Show full text]
  • Drugs and Medical Devices Group
    The Deputy Administrator of the Drug Enforcement Administration (DEA) issued a notice of intent temporarily placing the substance 2,5-dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7), including its optical isomers, salts, and salts of isomers into Schedule I of the Federal Controlled Substances Act (CSA). 2C-T-7 is structurally related to the Schedule I substance 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and it has those structural features of phenethylamines which are necessary for stimulant and/or hallucinogenic activity. There is no approved therapeutic use of 2C-T-7 in the United States, and the safety of this substance has never been demonstrated. This action was based on the following: (1) 2,5-dimethoxy-4-(n)-propylthiophenethylamine is structurally and pharmacologically related to other Schedule I hallucinogens; (2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has no accepted therapeutic use in the United States and is not safe for use under medical supervision; and, (3) 2,5-dimethoxy-4-(n)-propylthiophenethylamine has a high potential for abuse, similar to other Schedule I phenethylamines. Pursuant to Section 481.034(g), as amended by the 75th legislature, of the Texas Controlled Substances Act, Chapter 481, Health and Safety Code, at least thirty-one days have expired since notice of the above referenced action was published in the Federal Register, and in my capacity as Commissioner of the Texas Department of Health, I do hereby order that the substance 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers be added to Schedule I of the Texas Controlled Substances Act.
    [Show full text]
  • The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 6-2020 The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting Robert J. Kohler Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Biological Psychology Commons Recommended Citation Kohler, Robert J., "The Effects of Low Dose Lysergic Acid Diethylamide Administration in a Rodent Model of Delay Discounting" (2020). Dissertations. 3565. https://scholarworks.wmich.edu/dissertations/3565 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING by Robert J. Kohler A dissertation submitted to the Graduate College In partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University June 2020 Doctoral Committee: Lisa Baker, Ph.D., Chair Anthony DeFulio, Ph.D. Cynthia Pietras, Ph.D. John Spitsbergen, Ph.D. Copyright by Robert J. Kohler 2020 THE EFFECTS OF LOW DOSE LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION IN A RODENT MODEL OF DELAY DISCOUNTING Robert J. Kohler, Ph.D. Western Michigan University, 2020 The resurgence of Lysergic Acid Diethylamide (LSD) as a therapeutic tool requires a revival in research, both basic and clinical, to bridge gaps in knowledge left from a previous generation of work. Currently, no study has been published with the intent of establishing optimal microdose concentrations of LSD in an animal model.
    [Show full text]
  • Lysergic Acid Diethylamide (LSD) Promotes Social Behavior Through Mtorc1 in the Excitatory Neurotransmission
    Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Danilo De Gregorioa,b,1, Jelena Popicb,2,3, Justine P. Ennsa,3, Antonio Inserraa,3, Agnieszka Skaleckab, Athanasios Markopoulosa, Luca Posaa, Martha Lopez-Canula, He Qianzia, Christopher K. Laffertyc, Jonathan P. Brittc, Stefano Comaia,d, Argel Aguilar-Vallese, Nahum Sonenbergb,1,4, and Gabriella Gobbia,f,1,4 aNeurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1; bDepartment of Biochemistry, McGill University, Montreal, QC, Canada, H3A 1A3; cDepartment of Psychology, McGill University, Montreal, QC, Canada, H3A 1B1; dDivision of Neuroscience, Vita Salute San Raffaele University, 20132 Milan, Italy; eDepartment of Neuroscience, Carleton University, Ottawa, ON, Canada, K1S 5B6; and fMcGill University Health Center, Montreal, QC, Canada, H3A 1A1 Contributed by Nahum Sonenberg, November 10, 2020 (sent for review October 5, 2020; reviewed by Marc G. Caron and Mark Geyer) Clinical studies have reported that the psychedelic lysergic acid receptor (6), but also displays affinity for the 5-HT1A receptor diethylamide (LSD) enhances empathy and social behavior (SB) in (7–9). Several studies have demonstrated that LSD modulates humans, but its mechanism of action remains elusive. Using a glutamatergic neurotransmission and, indirectly, the α-amino- multidisciplinary approach including in vivo electrophysiology, 3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. optogenetics, behavioral paradigms, and molecular biology, the Indeed, in vitro studies have shown that LSD increased the ex- effects of LSD on SB and glutamatergic neurotransmission in the citatory response of interneurons in the piriform cortex following medial prefrontal cortex (mPFC) were studied in male mice.
    [Show full text]
  • 4-Bromo-2,5-Dimethoxyphenethylamine (Street Names: 2C-B, Nexus, 2’S, Toonies, Bromo, Spectrum, Venus)
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 4-Bromo-2,5-Dimethoxyphenethylamine (Street Names: 2C-B, Nexus, 2’s, Toonies, Bromo, Spectrum, Venus) February 2020 User Population: Introduction: 2C-B is used by the same population as those using 4-Bromo-2,5-dimethoxyphenethylamine (2C-B, 4- “Ecstasy” and other club drugs; high school and college bromo-2,5-DMPEA) is a synthetic schedule I hallucinogen. students, and other young adults who frequent “rave” or It is abused for its hallucinogenic effects primarily as a club “techno” parties. drug in the rave culture and “circuit” party scene. Illicit Distribution: Licit Uses: 2C-B is distributed as tablets, capsules, or in powder 2C-B has no approved medical uses in the United form. Usually sold as MDMA, a single dosage unit of 2C-B States. typically sells for $10 to $30 per tablet. The illicit source of 2C-B currently available on the street has not been Chemistry and Pharmacology: identified by DEA. Prior to its control, DEA seized both 4-Bromo-2,5-dimethoxyphenethylamine is closely clandestine laboratories and illicit “repacking shops.” As related to the phenylisopropylamine hallucinogen 1-(4- the name implies, these shops would repackage and bromo-2, 5-dimethoxyphenyl)-2-aminopropane (DOB) and reformulate the doses of the tablets prior to illicit sales. is referred to as alpha-desmethyl DOB. 2C-B produces According to the System to Retrieve Information from effects similar to 2,5-dimethoxy-4-methylamphetamine Drug Evidence (STRIDE) data, the first recorded (DOM) and DOB. 2C-B displays high affinity for central submission by law enforcement to DEA forensic serotonin receptors.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • G.S. 90-89 Page 1 § 90-89. Schedule I Controlled Substances. This
    § 90-89. Schedule I controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule: (1) Opiates. – Any of the following opiates or opioids, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetyl-alpha-methylfentanyl (N[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacet amide). b. Acetylmethadol. c. Repealed by Session Laws 1987, c. 412, s. 2. d. Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl/-4-piperidinyl]-N-phenylpro panamide). e. Allylprodine. f. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate and LAAM). g. Alphameprodine. h. Alphamethadol. i. Alpha-methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionalilide; 1(1-methyl-2-phenyl-ethyl)-4-(N-propanilido) piperidine). j. Benzethidine. k. Betacetylmethadol. l. Beta-hydroxfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide ). m. Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpro panamide). n. Betameprodine. o. Betamethadol. p. Betaprodine. q. Clonitazene. r. Dextromoramide. s. Diampromide. t. Diethylthiambutene. u.
    [Show full text]
  • Alltech® Drug Standards for the Forensic, Clinical & Pharmaceutical Industries OH
    Alltech® Drug Standards For the Forensic, Clinical & Pharmaceutical Industries OH H3C H H H3C H HO Catalog #505B Our Company Welcome to the Grace's Alltech® Drug Standards Catalog W. R. Grace has manufactured high-quality silica for over 150 years. Grace has been behind the scenes for the past 30 years supplying silica to the chromatography industry. Now we’re in the forefront moving beyond silica, developing and delivering innovative complementary products direct to the customer. Grace Davison Discovery Sciences was founded on Grace’s core strength as a premier manufacturer of differentiated media for SPE, Flash, HPLC, and Process chromatography. This core competency is further enhanced by bringing seven well-known global separations companies together, creating a powerful new single source for all your chromatography needs. A Full Portfolio of Chromatography Products to Support Drug Standards: • HPLC Columns • HPLC Accessories • Flash Products • TLC Products • GC Columns • GC Accessories • SPE and Filtration • Equipment • Syringes • Tubing • Vials For complete details, download the Chromatography Essentials catalog from the Grace web site or contact your customer service representative. Alltech - Part of the Grace Family of Products In 2004, Alltech Associates Inc. was acquired by Grace along with the Alltech® Drug Standards product line. Through investment in research and strategic acquisitions, Grace has expanded our product range and global reach while drawing upon the support of the Grace corporate infrastructure and more than 6000 employees globally to support scientific research and analysis worldwide. With key manufacturing sites in North and South America, Europe, and Asia, plus an extensive international sales and distribution network, separation scientists throughout the world can count on timely delivery and expert local technical service.
    [Show full text]
  • Novel Hallucinogens and Plant-Derived Highs
    Novel Hallucinogens and Plant-Derived Highs Emily Dye Forensic Chemist Special Testing and Research Laboratory Drug Enforcement Administration Outline • Hallucinogens • Plant-Derived Highs – 2C Compounds – Kratom – NBOMe Compounds – Fly Agaric Mushrooms – DOX Compounds – Kava Kava – Kanna • Empathogens – Aminoindanes – APDB – APB DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds • Psychedelic phenethylamines • Synthesized by Alexander Shulgin – Published in PiHKAL • 27 known compounds – Most common: 2C-C, 2C-B, and 2C-I DEA Special Testing and Research Laboratory Emerging Trends Program 2C Compounds DEA Special Testing and Research Laboratory Emerging Trends Program 2C-B-FLY • Psychedelic phenethylamine • Synthesized by Aaron Monte www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program Bromo-DragonFLY • Psychedelic phenethylamine • Synthesized in the lab of David Nichols • Deaths associated with misrepresentation as 2C-B-FLY www.erowid.org DEA Special Testing and Research Laboratory Emerging Trends Program NBOMe Compounds • Hallucinogenic phenethylamines • Synthesized by Heim, et al. • Isomers can be distinguished via RT and MS DEA Special Testing and Research Laboratory Emerging Trends Program Name R1 R2 R3 R4 Name R1 R2 R3 R4 25B-NB2OMe Br OCH3 H H 25N-NB2OMe NO2 OCH3 H H 25B-NB3OMe Br H OCH3 H 25N-NB3OMe NO2 H OCH3 H 25B-NB4OMe Br H H OCH3 25N-NB4OMe NO2 H H OCH3 25C-NB2OMe Cl OCH3 H H 25P-NB2OMe CH2CH2CH3 OCH3 H H 25C-NB3OMe Cl H OCH3 H 25P-NB3OMe CH2CH2CH3 H OCH3 H 25C-NB4OMe
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]
  • Update on Clandestine Amphetamines and Their Analogues Recently Seen in Japan
    14 Journal of Health Science, 48(1) 14–21 (2002) — Minireview — Update on Clandestine Amphetamines and Their Analogues Recently Seen in Japan Munehiro Katagi* and Hitoshi Tsuchihashi Forensic Science Laboratory, Osaka Prefectural Police H.Q., 1–3–18 Hommachi, Chuo-ku, Osaka 541–0053, Japan (Received October 12, 2001) Amphetamines and their analogues have undergone a cycle of popularity as recreational drugs in Japan. The current wave of popularity began in the early 1990s and spread throughout the country. More recently, not only 3,4- methylenedioxymethamphetamine (MDMA) but also other designer amphetamines analogues, including p- methoxyamphetamine (PMA), 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2), etc., have been extensively and increasingly abused, mainly among juveniles. This minireview presents an update on the amphetamines and their analogues by focusing on clandestine tablets encountered in Japan recently. Key words —–— amphetamines, amphetamine analogue, clandestine tablet INTRODUCTION identification of amphetamines and their analogues have recently been reported.6–10) Drug abuse, which affects human nature and This minireview presents an update on amphet- causes numerous crimes, has become a serious prob- amines and their analogues which have been sub- lem throughout the world. d-Methamphetamine hy- mitted to our laboratory for forensic drug analysis drochloride (d-MA HCl) crystalline has been the primarily in tablet form. most extensively and increasingly used illicit drug in Japan, although l-MA HCl crystalline has also Amphetamines often been encountered in the last four autumn sea- In most cases, amphetamines contained in clan- sons.1–3) Additionally, d-dimethylamphetamine hy- destine tablets seized in Japan have been found to drochloride (d-DMA HCl) crystalline emerged in be MA.
    [Show full text]
  • ATR Expands Embryonic Stem Cell Fate Potential in Response to Replication
    RESEARCH ARTICLE ATR expands embryonic stem cell fate potential in response to replication stress Sina Atashpaz1†*, Sara Samadi Shams1†, Javier Martin Gonzalez2, Endre Sebestye´ n1‡, Negar Arghavanifard1,3, Andrea Gnocchi1,3, Eliene Albers4, Simone Minardi1,5, Giovanni Faga6, Paolo Soffientini1, Elisa Allievi5, Valeria Cancila7, Angela Bachi1,O´ scar Ferna´ ndez-Capetillo8,9, Claudio Tripodo7, Francesco Ferrari1, Andre´ s Joaquin Lo´ pez-Contreras4, Vincenzo Costanzo1,3* 1IFOM-The FIRC Institute of Molecular Oncology, Milan, Italy; 2Transgenic Core Facility, University of Copenhagen, Copenhagen, Denmark; 3Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; 4Center for Chromosome Stability and Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark; 5Cogentech, IFOM-The FIRC Institute of Molecular Oncology Milan, Milan, Italy; 6Experimental Therapeutics Program, IFOM-The FIRC Institute of Molecular Oncology, Milan, Italy; 7Tumor Immunology Unit, Department of Health Sciences, Human Pathology Section, University of Palermo School of Medicine Palermo, Palermo, Italy; 8Spanish National Cancer Research Center, Madrid, Spain; 9Science for Life Laboratory, Division of Genome Biology, Department of Medical *For correspondence: Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden [email protected] (SA); [email protected] (VC) †These authors contributed equally to this work Abstract Unrepaired DNA damage during embryonic development
    [Show full text]